Sino Biological, Inc. has introduced 4RISE™, an integrated wet-lab validation solution aimed at bridging the gap between AI-generated protein designs and experimental proof. The announcement, made via NEWMEDIAWIRE, highlights a growing need in the biotechnology sector: while AI can rapidly generate protein candidates, confirming their expression, binding, and biological function remains a labor-intensive and time-consuming process.
The 4RISE™ platform is built on four pillars—Rapid, In-Depth, Seamless, and Empirical—that together streamline the validation workflow. Under “Rapid,” Sino Biological’s XPressMAX™ cell-free protein synthesis enables recombinant protein expression in approximately three hours, with success rates exceeding 99% in established workflows. Combined with more than 11,000 ready-to-use target proteins and high-throughput SPR/BLI analysis, the platform can deliver AI-ready binding data in as little as three days. This speed is critical for iterative design cycles, where rapid feedback can significantly accelerate the identification of promising candidates.
The “In-Depth” component extends validation beyond simple binding assays to include developability and functional assessments. With over 20 developability assays and a range of molecular and cell-based functional tests, researchers can evaluate candidate quality and biological activity more comprehensively. This matters because AI-designed molecules must not only bind their targets but also exhibit drug-like properties and desired biological effects to advance toward clinical development.
“Seamless” integration is achieved through complementary cell-free and mammalian expression platforms, coupled with an extensive in-house target protein portfolio. This allows for antibody production, binding characterization, developability assessment, and functional validation to be performed under one roof, reducing handoff delays and ensuring consistency. The “Empirical” pillar underscores Sino Biological’s practical experience: the company has supported diverse AI-designed molecules, including miniproteins, VHH, scFv, Fab, IgG, enzymes, and cytokines, and has collaborated with more than 50 AI companies.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, noted, “AI-driven discovery requires more than computational predictions. Researchers need reliable experimental evidence to evaluate candidates and guide subsequent design decisions.” The launch of 4RISE™ directly addresses this need by providing a structured, high-throughput validation pipeline that generates AI-ready data and supports API access for downstream integration.
The implications for the biotech industry are substantial. As AI becomes more entrenched in drug discovery, the ability to rapidly and reliably validate AI-designed molecules will be a key differentiator. Sino Biological’s 4RISE™ offers a comprehensive solution that could shorten development timelines and increase the success rate of AI-driven biologics. For researchers and companies leveraging AI, this integrated approach may reduce the friction between design and experimental validation, ultimately bringing innovative therapeutics to patients faster. More details about the 4RISE™ High-Throughput Wet-Lab Validation Services are available on the company’s website at https://www.sinobiological.com/services/htp-platform-for-ai-driven-antibody-discovery.
